Patterns of β2-agonist use
| Budesonide–formoterol as needed | Maintenance budesonide | |
| Patients | 55 | 55 |
| β2-agonist | Formoterol 6 μg | Terbutaline 250 μg |
| Daily β2-agonist actuations# | ||
| Mean±sd | 0.9±0.7 | 0.5±0.6 |
| Median (IQR) | 0.8 (0.4–1.3) | 0.3 (0.1–0.6) |
| Range (minimum–maximum) | 0.0–3.4 | 0.0–2.7 |
| Maximum actuations in a single day | ||
| Mean±sd | 6.0±2.9 | 8.0±10.9 |
| Median (IQR) | 5 (4–8) | 6 (3–9.5) |
| Range (minimum–maximum) | 1–13 | 0–80 |
| Days ≥2 actuations of formoterol or ≥4 actuations of terbutaline | ||
| Total days across all participants in the whole study n | 4175 | 694 |
| Mean±sd | 75.9±72.8 | 12.6±23.5 |
| Median (IQR) | 48 (15–114) | 3 (0–14.5) |
| Range (minimum–maximum) | 0–329 | 0–139 |
| Days ≥4 actuations of formoterol or ≥8 actuations of terbutaline | ||
| Total days across all participants in the whole study n | 675 | 94 |
| Mean±sd | 12.3±26.0 | 1.7±3.9 |
| Median (IQR) | 4 (1–10) | 0 (0–2) |
| Range (minimum–maximum) | 0–153 | 0–21 |
IQR: interquartile range. #: data previously reported in the main publication of the PRACTICAL study [21] but presented again here for illustrative purposes.